25.06.2012 • News

Lonza, Biowa Sign License Agreements with FivePrime Therapeutics

FivePrime Therapeutics has entered into research and commercial agreements with Biowa and Lonza to use their Potelligent CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of Biowa's engineered glycosylation Potellingent Technology with the advantages of Lonza's proprietary GS Gene Expression Systems, which includes the industry-leading CHOK1SV cell line.

 

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read